CMS (867.HK; 8A8.SG): NDA for the Seasonal Allergic Rhinitis Indication of Class 1 Innovative Drug MG-K10 Accepted in China

SHENZHEN, CHINA – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that the New Drug Application (NDA) in China for the Seasonal Allergic Rhinitis (SAR) indication of MG-K10 (generic name: Comekibart Injection, “MG-K10” or the “Product”), a Class 1 innovative drug anti-IL-4Rα… Read More

Busan-Based Startup InsightMatches Launches AI Networking Platform SENS, Redefining Event Connections

Busan-based AI platform company InsightMatches has officially launched SENS, an AI-powered event matchmaking platform designed to transform how people connect at live events. South Korea, 24th Apr 2026 – SENS introduces a data-driven approach to networking at conferences, festivals, and corporate gatherings, replacing traditional methods… Read More